Page 145 - Haematologica May 2020

MLL-rearranged AML requires MN1
leukemia with normal cytogenetics. Blood.
2006;108(12):3898-3905.
9. Langer C, Marcucci G, Holland KB, et al.
Prognostic importance of MN1 transcript levels, and biologic insights from MN1- associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2009; 27(19):3198-3204.
10. Schwind S, Marcucci G, Kohlschmidt J, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 2011;118(15): 4188-4198.
11. Haferlach C, Kern W, Schindela S, et al. Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognos- tic information to cytogenetics and molec- ular mutations in adult acute myeloid leukemia. Genes Chromosomes Cancer. 2012;51(3):257-265.
12. Carella C, Bonten J, Sirma S, et al. MN1 overexpression is an important step in the development of inv(16) AML. Leukemia. 2007;21(8):1679-1690.
13. Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is an independent prognos- tic factor and allows refined risk stratifica- tion in cytogenetically normal acute myeloid leukemia: a comprehensive analy- sis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol. 2009;27(30):5031-5038.
14. Riedel SS, Haladyna JN, Bezzant M, et al. MLL1 and DOT1L cooperate with menin- gioma-1 to induce acute myeloid leukemia. J Clin Invest. 2016;126(4):1438-1450.
15. Sharma A, Yun H, Jyotsana N, et al. Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia. 2015;29(1):157-168.
16. van Wely KH, Molijn AC, Buijs A, et al. The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR- mediated transcription. Oncogene. 2003;22(5):699-709.
17. van Wely KH, Meester-Smoor MA, Janssen MJ, Aarnoudse AJ, Grosveld GC, Zwarthoff EC. The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR- mediated transcription. Oncogene.
2007;26(39):5733-5740.
18. Slape C, Hartung H, Lin YW, Bies J, Wolff
L, Aplan PD. Retroviral insertional mutage- nesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transfor- mation. Cancer Res. 2007;67(11):5148- 5155.
19. Caudell D, Harper DP, Novak RL, et al. Retroviral insertional mutagenesis identi- fies Zeb2 activation as a novel leuke- mogenic collaborating event in CALM- AF10 transgenic mice. Blood. 2010;115(6): 1194-1203.
20. Liu T, Jankovic D, Brault L, et al. Functional characterization of high levels of menin- gioma 1 as collaborating oncogene in acute leukemia. Leukemia. 2010;24(3):601-612.
21. Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008;111(8):4297-4308.
22. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syn- drome--long-term efficacy and genotoxici- ty. Sci Transl Med. 2014;6(227):227ra33.
23. Heuser M, Yun H, Berg T, et al. Cell of ori- gin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell. 2011;20(1):39-52.
24. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progeni- tor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-822.
25. Bernt KM, Zhu N, Sinha AU, et al. MLL- rearranged leukemia is dependent on aber- rant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66-78.
26. Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemo- genesis. Blood. 2011;117(25):6912-6922.
27. Sharma A, Jyotsana N, Lai CK, et al. Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. Curr Cancer Drug Targets. 2016; 16(9):818-828.
28. Meester-Smoor MA, Vermeij M, van Helmond MJ, et al. Targeted disruption of the Mn1 oncogene results in severe defects in development of membranous bones of the cranial skeleton. Mol Cell Biol. 2005;25(10):4229-4236.
29. Heuser M, Sly LM, Argiropoulos B, et al.
Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood. 2009;114(19):3983-3993.
30. Reimer J, Knoss S, Labuhn M, et al. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica. 2017;102(9):1558-1566.
31. Stemmer M, Thumberger T, Del Sol Keyer M, Wittbrodt J, Mateo JL. CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool. PLoS One. 2015;10(4):e0124633.
32. Jyotsana N, Sharma A, Chaturvedi A, et al. RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo. Leukemia. 2018;32(1):224-226.
33. Deshpande AJ, Deshpande A, Sinha AU, et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014;26(6):896-908.
34. Huang Y, Sitwala K, Bronstein J, et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood. 2012;119(2):388-398.
35. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007;26(47):6766-6776.
36. Brumatti G, Salmanidis M, Kok CH, et al. HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget. 2013;4(11):1933-1947.
37. Zhou J, Wu J, Li B, et al. PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. Leukemia. 2014;28(7):1436-1448.
38. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17(18):2298-2307.
39. Tan J, Jones M, Koseki H, et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell. 2011;20(5):563-575.
40. Zhu N, Chen M, Eng R, et al. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest. 2016;126(3):997-1011.
41. Ghosh J, Kobayashi M, Ramdas B, et al. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance. J Clin Invest. 2016;126(7):2621-2625.
haematologica | 2020; 105(5)
1305